BoNT/A Protease Domain Arginine Substitutions for Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Botulinum neurotoxin (BoNT) treatments face limitations due to the generation of neutralizing antibodies and adverse effects such as ptosis and diplopia, which reduce their efficacy and safety, particularly at higher doses used for muscle spasms.
Innovation Solution
The development of modified BoNT/A protease domains with arginine substitutions at specific lysine residues enhances the efficacy and therapeutic duration of BoNT/A, reducing the likelihood of antibody generation and systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If higher doses of BoNT/A are used to treat muscle spasms, then therapeutic efficacy is improved, but the generation of neutralizing antibodies and adverse effects increases
Solution Approach 1:
The patent applies parameter changes by substituting lysine residues with arginine residues at specific positions (K11, K41, K212, K272, K289, K291, K299, K318, K335, K337, K340, K343, K356, K375, K381, Y387, M411, and K415) in the protease domain of BoNT/A. This amino acid substitution changes the chemical properties of the toxin surface, reducing immunogenicity while preserving or enhancing protease activity, thereby treating muscle spasms with lower doses that do not trigger neutralizing antibody formation
2Duration of action of moving object
If higher doses of BoNT/A are administered, then therapeutic duration is extended, but systemic toxicity and adverse effects such as ptosis and diplopia increase
Solution Approach 1:
The patent applies local quality by making specific modifications only to the protease domain of BoNT/A while leaving other domains unchanged. The lysine-to-arginine substitutions are targeted at specific positions on the surface of the protease domain, creating localized changes that reduce systemic immunogenicity and toxicity while maintaining the localized therapeutic effect at the injection site, thereby extending therapeutic duration without increasing systemic adverse effects
3Quantity of substance
If the efficacy of individual toxin molecules is enhanced to lower doses, then neutralizing antibody generation is reduced, but the complexity of toxin engineering increases
Solution Approach 1:
The patent systematically changes multiple parameters simultaneously by substituting 18 specific lysine residues with arginine residues at predetermined positions in the protease domain. This comprehensive parameter change approach was guided by structural analysis and computational modeling to predict immunogenicity reduction, allowing for enhanced efficacy at lower doses through a methodical rather than trial-and-error engineering process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified BoNT/A protease domains demonstrate increased catalytic activity and longer therapeutic duration with lower systemic toxicity, providing enhanced therapeutic efficacy and reduced antibody induction compared to wild-type BoNT/A.
Implementation Method 1
Botulinum neurotoxins (BoNTs) are a family of bacterial toxins that target and enter nerve terminals and then act as a protease to cleave key proteins required for neurotransmitter release
Data Source
AI summary
Disclosed herein are modified Clostridial Botulinum neurotoxin (BoNT) polypeptides with a modified protease domains of Clostridial Botulinum serotype A1 or A2. Modifications include substitution amino acid mutations, isolated modified protease domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.